| Title |
Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, June 2017
|
| DOI | 10.2147/tcrm.s117321 |
| Pubmed ID | |
| Authors |
Marco Solmi, Andrea Murru, Isabella Pacchiarotti, Juan Undurraga, Nicola Veronese, Michele Fornaro, Brendon Stubbs, Francesco Monaco, Eduard Vieta, Mary V Seeman, Christoph U Correll, André F Carvalho |
X Demographics
The data shown below were collected from the profiles of 14 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 21% |
| United Kingdom | 2 | 14% |
| Canada | 1 | 7% |
| Sweden | 1 | 7% |
| Italy | 1 | 7% |
| Unknown | 6 | 43% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 71% |
| Scientists | 2 | 14% |
| Practitioners (doctors, other healthcare professionals) | 2 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 541 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 541 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 68 | 13% |
| Student > Bachelor | 58 | 11% |
| Researcher | 50 | 9% |
| Student > Ph. D. Student | 46 | 9% |
| Other | 44 | 8% |
| Other | 107 | 20% |
| Unknown | 168 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 158 | 29% |
| Pharmacology, Toxicology and Pharmaceutical Science | 41 | 8% |
| Psychology | 30 | 6% |
| Neuroscience | 29 | 5% |
| Nursing and Health Professions | 25 | 5% |
| Other | 66 | 12% |
| Unknown | 192 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 May 2022.
All research outputs
#3,884,849
of 25,998,826 outputs
Outputs from Therapeutics and Clinical Risk Management
#189
of 1,331 outputs
Outputs of similar age
#67,028
of 334,438 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#4
of 25 outputs
Altmetric has tracked 25,998,826 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,331 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 334,438 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.